sanger sequencing traces (Eurofins)
Structured Review

Sanger Sequencing Traces, supplied by Eurofins, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sequence+traces/sanger+sequencing/pmc12802944-100-13-22
Average 86 stars, based on 1 article reviews
Images
1) Product Images from "Optimized CRISPR-Cas9 system for efficient engineering of ecDNA in cancer cells"
Article Title: Optimized CRISPR-Cas9 system for efficient engineering of ecDNA in cancer cells
Journal: Nucleic Acids Research
doi: 10.1093/nar/gkag005
Figure Legend Snippet: ecDNA knock-in efficiency of standard and safeguard sgRNAs. ( A ) Schematic showing insertion of a 96-mer TetO repeat sequence into ecDNA of CORL23 cells. See Material and Methods for details of the knock-in system. ( B ) Quantification of CORL23 cell numbers after expression of all-in-one CRISPR plasmids with the indicated sgRNAs and the knock-in template plasmid. Data represent mean ± SD for n = 3 biological replicates. Statistical significance was assessed using a two-sided Student’s t -test. ( C ) Experimental scheme for DNA FISH analyses shown in panels (D–F). (D–F) Box-and-whisker plots showing copy numbers of ( D ) MYC ecDNA and ( E ) TetO knock-in ecDNA in cells transfected with all-in-one CRISPR plasmids with the indicated sgRNAs and the knock-in template plasmid. Panel ( F ) shows the fraction of MYC ecDNA carrying the TetO knock-in sequence. Sample sizes ( n ) are shown below sgRNA labels. Statistical significance was assessed using a Wilcoxon rank-sum test.
Techniques Used: Knock-In, Sequencing, Expressing, CRISPR, Plasmid Preparation, Whisker Assay, Transfection
Figure Legend Snippet: Application of the safeguard sgRNA system in ecDNA-positive CORL23 cells. ( A ) AmpliconArchitect analysis showing the presence of ecDNA structures involving the MYC and PVT1 loci in CORL23 cells.( B ) IGV snapshot showing genome sequence profiles at the MYC and PVT1 loci. ( C ) Representative FISH images of CORL23 cells using an MYC locus probe (red) together with a chromosome 8 probe (green; control for the MYC -containing chromosome). Two representative single cells with different MYC ecDNA copy numbers are shown. Scale bar, 10 µm. ( D ) Schematic illustration of the proposed molecular mechanism by which safeguard sgRNAs fine-tune Cas9 activity. Cytosine extensions decrease Cas9 activity and attenuate Cas9-mediated DNA cleavage via multiple mechanisms, including reduced sgRNA synthesis and impaired target loading efficiency of Cas9–sgRNA RNP complexes (left). When using potent sgRNAs, [C]-extended sgRNAs exhibited decreased bi-allelic indels on chromosomal targets and increased mono-allelic indels in a length-dependent manner (right). This figure was adapted from Kawamata et al. , licensed under the CC BY 4.0. ( E ) Schematic of all-in-one CRISPR plasmids expressing standard and safeguard sgRNAs. ( F ) Western blot analysis of FLAG-tagged Cas9 proteins expressed from the indicated all-in-one plasmids in CORL23 cells. ( G ) Quantification of sgRNA expression levels by RT-qPCR. Left, normalized expression values; right, normalized values multiplied by 1000 and log 2 -transformed. Data represent mean ± SD for n = 3 technical replicates. Statistical significance was assessed using a two-sided Student’s t -test.
Techniques Used: Sequencing, Control, Activity Assay, CRISPR, Expressing, Western Blot, Quantitative RT-PCR, Transformation Assay
Related Articles
Sequencing:Article Title: Molecular diagnosis of Helicobacter pylori infection in gastric biopsies: Evaluation of the Amplidiag ® H. pylori + ClariR assay. Article Snippet: Helicobacter pylori is a Gram‐negative microaerophilic bacterium that typically establishes a lifelong infection in humans after its acquisi‐ tion during childhood.1 Gastric chronic infection with H. pylori causes many gastrointestinal diseases including peptic ulcers, gastritis, and gastric carcinoma.. The prevention of gastric cancer and complica‐ tions associated with ulcers depends on the successful eradication of H. pylori.2,3 In 1997, first‐line treatment was based on a 7‐day triple therapy with a proton‐pump inhibitor (PPI) and two of the following Received: 24 July 2018 | Revised: 15 November 2018 | Accepted: 16 November 2018 DOI: 10.1111/hel.12560 |

